Herman Burger
Overview
Explore the profile of Herman Burger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
1045
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wiemer E, Wozniak A, Burger H, Smid M, Floris G, Nzokirantevye A, et al.
Eur J Cancer
. 2017 Feb;
75:33-40.
PMID: 28214655
Background: Recent phase II and III clinical trials demonstrated anti-tumour activity of eribulin, a tubulin-interacting cytotoxic agent, in patients with metastatic soft tissue sarcoma (STS). In this exploratory study, we...
2.
de Morree E, Bottcher R, van Soest R, Aghai A, de Ridder C, Gibson A, et al.
Br J Cancer
. 2016 Aug;
115(6):674-81.
PMID: 27537383
Background: Both taxanes, docetaxel and cabazitaxel, are effective treatments for metastatic castration-resistant prostate cancer (mCRPC). However, resistance to taxanes is common. Our objective was to investigate mechanisms of taxane resistance...
3.
de Morree E, van Soest R, Aghai A, de Ridder C, de Bruijn P, Moghaddam-Helmantel I, et al.
Prostate
. 2016 Mar;
76(10):927-36.
PMID: 26997363
Background: Resistance to docetaxel is common in metastatic castration-resistant prostate cancer (mCRPC) and may be caused by sub-therapeutic intratumoral drug concentrations. Cabazitaxel demonstrated survival benefit in docetaxel-pretreated and docetaxel-refractory patients....
4.
Burger H, den Dekker A, Segeletz S, Boersma A, de Bruijn P, Debiec-Rychter M, et al.
Mol Pharmacol
. 2015 Jun;
88(3):477-87.
PMID: 26108972
The intracellular uptake and retention (IUR) of imatinib is reported to be controlled by the influx transporter SLC22A1 (organic cation transporter 1). We recently hypothesized that alternative uptake and/or retention...
5.
Binkhorst L, Kloth J, de Wit A, de Bruijn P, Lam M, Chaves I, et al.
Breast Cancer Res Treat
. 2015 Jun;
152(1):119-128.
PMID: 26050156
The anti-estrogen tamoxifen is characterized by a large variability in response, partly due to pharmacokinetic differences. We examined circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients. Pharmacokinetic...
6.
Kloth J, Binkhorst L, de Wit A, de Bruijn P, Hamberg P, Lam M, et al.
Clin Pharmacokinet
. 2015 Feb;
54(8):851-8.
PMID: 25647628
Background And Objective: Circadian rhythms may influence the pharmacokinetics of drugs. This study aimed to elucidate whether the pharmacokinetics of the orally administered drug sunitinib are subject to circadian variation....
7.
van der Biessen D, Burger H, de Bruijn P, Lamers C, Naus N, Loferer H, et al.
Clin Cancer Res
. 2014 Jul;
20(18):4776-83.
PMID: 25024258
Purpose: RGB-286638 is a multitargeted inhibitor with targets comprising the family of cyclin-dependent kinases (CDK) and a range of other cancer-relevant tyrosine and serine/threonine kinases. The objectives of this first...
8.
Eskens F, Ramos F, Burger H, OBrien J, Piera A, de Jonge M, et al.
Clin Cancer Res
. 2013 Aug;
19(22):6296-304.
PMID: 23983259
Purpose: To assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of E7107 administered as 5-minute bolus infusions on days 1, 8, and 15 in a 28-day schedule. Experimental Design:...
9.
Burger H, Mathijssen R, Sparreboom A, Wiemer E
Blood
. 2013 Jun;
121(24):4965-6.
PMID: 23766461
No abstract available.
10.
Marshall J, Hwang J, Eskens F, Burger H, Malik S, Uttenreuther-Fischer M, et al.
Invest New Drugs
. 2012 Nov;
31(2):399-408.
PMID: 23161335
Background: A Phase I study to determine the maximum tolerated dose (MTD) and pharmacokinetics of afatinib (BIBW 2992), a novel irreversible ErbB Family Blocker, administered orally once daily in a...